查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573872

乳癌核心针活检 (CNB) 市场、机会、成长动力、产业趋势分析与预测，2024-2032 年

Breast Cancer Core Needle Biopsy (CNB) Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 110 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球乳癌核心针切片市场价值为7.765亿美元，由于乳癌发生率上升，导致早期诊断需求增加，预计2024年至2032年复合年增长率为7.8%。

世界卫生组织 (WHO) 报告称，到 2022 年，全球约有 230 万名女性被诊断出患有乳癌。女性对早期乳癌检测的认识不断提高，增加了对癌症​​筛检计画的需求，从而加大了对 CNB 等微创诊断程序的需求。

对癌症筛检和诊断服务的需求极大地推动了乳癌核心针活检市场的发展。影像技术和乳房活检设备的创新正在提高 CNB 的准确性和安全性，促进其在已开发市场和新兴市场的采用。

整个乳癌核心针活检产业根据影像引导技术、最终用户和地区进行分类。

超音波引导细分市场占据主导地位，预计在预测期内复合年增长率为 7.6%。它的突出源于其准确性和非侵入性方法。该技术利用即时超音波成像，精确定位可疑的乳房组织，确保从确切的关注区域采集活检样本。优点包括缩短手术时间、最小化患者不适以及立即实现活检部位可视化。其成本效益和与临床实践的无缝整合进一步巩固了其在乳癌核心针活检（CNB）市场的领先地位。

2023年，医院占据最大的市场份额，达到48.4%。他们的主导地位植根于广泛的诊断能力和最先进的设施。医院提供从超音波到乳房X光检查等一系列影像技术以及活检程序，确保提高准确性和患者护理。他们有能力处理复杂的病例，并得到专业医疗团队和全面后续护理的支持，丰富了诊断之旅。大量患者和强大的基础设施推动了这些诊断程序在医院的广泛采用。

由于乳癌发生率高以及对有效诊断解决方案的需求不断增长，2023年美国乳癌CNB市场价值为3.203亿美元。美国癌症协会指出，大约八分之一的女性（约占美国女性人口的 13%）将在一生中面临乳癌诊断。预计到 2024 年，乳癌将占女性新诊断癌症的近 30%。这项统计数据凸显了对高效诊断工具和程序的迫切需求。活检设备的持续技术进步和支持性报销政策支撑了市场的成长轨迹。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 乳癌盛行率上升
      • 乳癌诊断技术的技术进步
      • 提高早期诊断意识
      • 扩大研发
    • 产业陷阱与挑战
      • 对替代诊断方法的偏好
      • 严格的监管要求
  • 成长潜力分析
  • 监管环境
  • 技术景观
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按影像引导技术，2021 - 2032 年

  • 主要趋势
  • 立体定位引导
  • 超音波引导
  • 磁振造影 (MRI) 引导

第 6 章：市场估计与预测：按最终用户划分，2021 - 2032 年

  • 主要趋势
  • 医院
  • 癌症研究中心
  • 诊断中心
  • 研究和学术

第 7 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 8 章：公司简介

  • Aurora Imaging Technology Inc.
  • BD
  • Devicor Medical Products, Inc.
  • Fujifilm Holdings
  • Hologic, Inc.
  • Insight Medbotics
  • McLaren
  • Rye Radiology
  • Siemens Healthcare Private Limited
  • Sentinelle Medical Inc.
  • Tampa General
简介目录
Product Code: 11100

The Global Breast Cancer Core Needle Biopsy Market was valued at USD 776.5 million in 2023 and is projected to expand at a CAGR of 7.8% from 2024 to 2032, driven by the rising incidence of breast cancer, leading to heightened demand for early diagnosis.

The World Health Organization (WHO) reported that around 2.3 million women were diagnosed with breast cancer worldwide in 2022. This trend has spurred the adoption of various biopsy techniques, notably Core Needle Biopsy (CNB). Growing awareness among women about early breast cancer detection has increased demand for cancer screening programs, intensifying the need for minimally invasive diagnostic procedures like CNB.

The demand for cancer screening and diagnostic services has significantly propelled the market for breast cancer core needle biopsies. Innovations in imaging technologies and breast biopsy devices are enhancing the accuracy and safety of CNB, boosting its adoption in both developed and emerging markets.

The overall breast cancer core needle biopsy industry is classified based on image-guided technology, end-user, and region.

The ultrasound-guided segment dominates the market and is projected to grow at a CAGR of 7.6% during the forecast period. Its prominence stems from its accuracy and non-invasive approach. Utilizing real-time ultrasound imaging, this technique precisely targets suspicious breast tissue, ensuring biopsy samples are taken from the exact area of concern. Benefits include reduced procedure time, minimal patient discomfort, and immediate biopsy site visualization. Its cost-effectiveness and seamless integration into clinical practices further cement its leading position in the breast cancer core needle biopsy (CNB) market.

In 2023, hospitals commanded the largest market share at 48.4%. Their dominance is rooted in extensive diagnostic capabilities and state-of-the-art facilities. Offering a suite of imaging technologies, from ultrasound to mammography, alongside biopsy procedures, hospitals ensure heightened accuracy and patient care. Their ability to manage intricate cases, backed by specialized medical teams and comprehensive follow-up care, enriches the diagnostic journey. High patient volumes and robust infrastructure drive the widespread adoption of these diagnostic procedures in hospitals.

In 2023, the U.S. breast cancer CNB market was valued at USD 320.3 million, due to a high breast cancer incidence and a growing demand for effective diagnostic solutions. The American Cancer Society notes that roughly 1 in 8 women, or about 13% of the U.S. female population, will face a breast cancer diagnosis in their lifetime. Projections for 2024 suggest breast cancer will represent nearly 30% of all new cancer diagnoses among females. This statistic highlights the urgent need for efficient diagnostic tools and procedures. Ongoing technological advancements in biopsy devices and supportive reimbursement policies bolster the market's growth trajectory.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of breast cancer
      • 3.2.1.2 Technological advancements in breast cancer diagnostics techniques
      • 3.2.1.3 Rising awareness for early diagnosis
      • 3.2.1.4 Expansion of research and development
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 Preference for alternative diagnostic methods
      • 3.2.2.2 Stringent regulatory requirements
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Technology landscape
  • 3.6 Future market trends
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Image-guidance Technology, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Stereotactic-guided
  • 5.3 Ultrasound-guided
  • 5.4 Magnetic resonance imaging (MRI)-guided

Chapter 6 Market Estimates and Forecast, By End-user, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hospitals
  • 6.3 Cancer research centers
  • 6.4 Diagnostic centers
  • 6.5 Research and academics

Chapter 7 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 France
    • 7.3.4 Spain
    • 7.3.5 Italy
    • 7.3.6 Netherlands
    • 7.3.7 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 South Korea
    • 7.4.6 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Mexico
    • 7.5.3 Rest of Latin America
  • 7.6 Middle East and Africa
    • 7.6.1 South Africa
    • 7.6.2 Saudi Arabia
    • 7.6.3 UAE
    • 7.6.4 Rest of Middle East and Africa

Chapter 8 Company Profiles

  • 8.1 Aurora Imaging Technology Inc.
  • 8.2 BD
  • 8.3 Devicor Medical Products, Inc.
  • 8.4 Fujifilm Holdings
  • 8.5 Hologic, Inc.
  • 8.6 Insight Medbotics
  • 8.7 McLaren
  • 8.8 Rye Radiology
  • 8.9 Siemens Healthcare Private Limited
  • 8.10 Sentinelle Medical Inc.
  • 8.11 Tampa General